Innoviva, Inc. continues to branch out from collecting royalties on inhaled respiratory medicines commercialized by GlaxoSmithKline Pharmaceuticals Ltd. to a company also developing and commercializing its own medicines, adding two approved drugs through its purchase of La Jolla Pharmaceutical Company, announced on 11 July. The deal also adds a commercial organization that could bring to market a recently acquired late-stage asset.
Innoviva Aims For Antibiotic Success With La Jolla, Entasis Acquisitions
$149m La Jolla Purchase Expands Hospital Presence
Having recently bought antibacterial developer Entasis, Innoviva adds approved antibiotic Xerava and hypotension drug Giapreza to its portfolio along with La Jolla’s established commercial organization.
